Beam Therapeutics BEAM Proceeds from sales of equity securities
Proceeds from sales of equity securities at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfEquityMethodInvestments.
The official record: Beam Therapeutics’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's proceeds from sales of equity securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Beam Therapeutics's proceeds from sales of equity securities?
- Beam Therapeutics (BEAM) reported proceeds from sales of equity securities of $63.79M in Q4 2025.
- What does proceeds from sales of equity securities mean?
- Cash received from selling equity securities (stocks, equity funds) from the investment portfolio.